Related Experiment Video

Updated: Aug 15, 2026

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

Metabolic drug interactions between angiogenic inhibitor, TNP-470 and anticancer agents in primary cultured

L Placidi1, E C Scott, D Eckoff

  • 1Department of Pharmacology and Toxicology, The Liver Center, Comprehensive Cancer Center, Division of Clinical Pharmacology, University of Alabama at Birmingham, 35294-0019, USA.

Drug Metabolism and Disposition: the Biological Fate of Chemicals
|April 30, 1999
PubMed

Insights

Investigating drug interactions, this study found that cyclophosphamide and taxol significantly alter TNP-470 metabolism in rhesus monkey hepatocytes. Understanding these metabolic changes is crucial for optimizing combination cancer therapies.

Area of Science:

  • Pharmacology
  • Drug Metabolism
  • Oncology

Background:

  • TNP-470 is a potent inhibitor of angiogenesis used in cancer therapy.
  • Potential metabolic drug interactions between TNP-470 and common anticancer agents require investigation.

Purpose of the Study:

  • To investigate in vitro metabolic drug interactions between TNP-470 and cyclophosphamide, taxol, and minocycline.
  • To understand the impact of these interactions on TNP-470 metabolism in rhesus monkey hepatocytes and microsomes.

Main Methods:

  • Primary cultured hepatocytes and liver microsomes from rhesus monkeys were used for in vitro incubations.
  • Hepatocytes were incubated with [3H]TNP-470 in the presence or absence of cyclophosphamide, taxol, or minocycline.
  • Metabolite concentrations and unchanged drug levels were quantified using analytical methods.

Main Results:

  • Cyclophosphamide increased unchanged TNP-470 and metabolite M-IV, while decreasing metabolite M-II.
  • Taxol decreased M-II levels and increased unchanged TNP-470 and M-IV.
  • Minocycline showed no significant effect on TNP-470 metabolism.
  • In vitro microsomal studies confirmed the observed cellular-level interactions.

Conclusions:

  • Cyclophosphamide and taxol significantly alter TNP-470 metabolism in rhesus monkey models.
  • These metabolic interactions are critical for understanding the enhanced antitumor activity observed in vivo.
  • Further research is needed to elucidate the clinical implications of these drug-drug interactions.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity09:32

Drug-Induced Senescence in Liver Cells Promotes M2 Macrophage Polarization: Implications for Tyrosine Kinase Inhibitor-Associated Hepatotoxicity

Published on: October 17, 2025

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Pharmacokinetics: Drug–Drug Interactions01:25

Pharmacokinetics: Drug–Drug Interactions

Drug interactions occur when the pharmacological effect of one drug is altered by another substance, either enhancing or diminishing its activity. The drug whose activity is altered is known as the object drug, and the substance causing the alteration is called the agent drug or the precipitant. The net effects of these interactions are mostly undesirable, leading to decreased effectiveness or increased adverse effects. In rare cases, interactions can be beneficial, such as the enhanced...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...